Alivus Life Sciences Ltd · ALIVUS
₹562 Cr
₹522 Cr
₹514 Cr
₹490 Cr
₹509 Cr
₹541 Cr
₹621 Cr
₹578 Cr
₹595 Cr
₹573 Cr
₹537 Cr
₹589 Cr
₹507 Cr
₹642 Cr
₹650 Cr
₹602 Cr
₹588 Cr
₹673 Cr
₹689 Cr
₹640 Cr
20-quarter listed-company comparison
Pharmaceuticals Bulk Drugs & Formulation Stocks in India
Pharmaceuticals Bulk Drugs & Formulation: Alivus Life Sciences Ltd owns the largest revenue base AND the fastest current growth.
01 · the index people search for
Nifty Pharmaceuticals Bulk Drugs & Formulation Index — Constituents & Performance
All 2 listed Indian Pharmaceuticals Bulk Drugs & Formulation companies are named here, largest first — the same constituent set people search for as the Nifty Pharmaceuticals Bulk Drugs & Formulation index. Every figure on this page is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
- Alivus Life Sciences Ltd₹17.0K Cr
- Amanta Healthcare Ltd₹607 Cr
02 · sector relative strength, before individual stocks
Is Pharmaceuticals Bulk Drugs & Formulation outperforming NIFTY 500?
Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over the last 52 weeks. Over 13 weeks the gap is a lead of 22.6%. 1 of 1 covered company currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is broad. Alivus Life Sciences Ltd is the strongest against the sector itself at +4.7%.
+22.6%Sector vs NIFTY 500 · 13 weeks
+27.5%Sector vs NIFTY 500 · 52 weeks
1/1Stocks leading NIFTY 500
1/1Stocks leading sector
Sector metric: 18.4 as of 2026-08-09 · BROADENING · falling.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over 52 weeks and 22.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself. Alivus Life Sciences Ltd leads with revenue of ₹2,590 crore, based on 2 of 2 comparable companies through Jun 2026.
Companies
2
complete canonical membership
Combined market value
₹17.6K Cr
Alivus Life Sciences Ltd
Revenue growing
2/2
positive TTM year-on-year growth
Beating NIFTY 500
1/1
positive Mansfield relative strength
Comparing 2 of 2
03 · research priority, made explicit
Best Pharmaceuticals Bulk Drugs & Formulation Stocks in India (Aug 2026), Ranked by Data
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Alivus Life Sciences Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 97% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Top 10 Pharmaceuticals Bulk Drugs & Formulation Stocks in India
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Alivus Life Sciences LtdALIVUS | 72.5/100Favorable setup97% evidence | LEADER | 22.6/35 Revenue 7.9% · PAT 21.6% · OPM change 4 pp 100% evidence | 20.0/25 ROCE 23.8% · OPM 33% 100% evidence | 11.2/20 P/E 27.4× · PEG 1.17 85% evidence | 18.7/20 RS sector 4.7% · RS bench 36.7% · 1Y 48.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 20 + 11.2 + 18.7 = 72.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Amanta Healthcare LtdAMANTA | 39.1/100Thin evidence · provisional57% evidence | BREAKING OUT | 5.9/35 Revenue 7.1% · PAT -8.3% · OPM change -1.7 pp 95% evidence | 13.2/25 ROCE 11.6% · OPM 21.1% 95% evidence | 10.0/20 P/E 39.6× · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 5.9 + 13.2 + 10 + 10 = 39.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
04 · what price has already done
Market action
Alivus Life Sciences Ltd has the strongest one-year price move in Pharmaceuticals Bulk Drugs & Formulation at +48.3%. It also leads on Mansfield relative strength against NIFTY at +36.7%. 1 of 1 covered company is above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Pharmaceuticals Bulk Drugs & Formulation itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · the story behind the numbers
Pharmaceuticals Bulk Drugs & Formulation — the story behind the numbers
This is the written read behind the Pharmaceuticals Bulk Drugs & Formulation figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 19 Apr 2026, so the words are older than the numbers. 5 themes are live here.
The sector is in a transition phase where high-margin CDMO and specialty portfolios are successfully offsetting generic price erosion. While profitability is at record levels, the divergence in capex strategies and elevated working capital cycles suggest that execution on new capacity utilization will be the key differentiator in FY27.
The Pharmaceuticals Bulk Drugs & Formulation sector is witnessing a period of margin expansion, with constituents reporting EBITDA margins in the 36.4% to 37.3% range. This performance is underpinned by a transition from commodity APIs to value-added segments.
How old this read is: STALE — this read comes from our Pharmaceuticals Bulk Drugs & Formulation sector brief dated 19 Apr 2026, about 4 months ago. The page says so rather than dressing it up, and a fresh sector dive replaces it the day it runs.
What is live in this sector right now
| Live theme | Severity | Evidence on file |
|---|---|---|
| Anticipated 5% price erosion in the generic API business due to competitive intensity.Named for ALIVUS | medium | “On the overall growth, you can take about 5% price erosion, Tarang. The balance is the volume growth.” Mitigated by next-generation process improvements and higher-margin new launches. |
| Includes US tariff uncertainties and local environmental penalties.Named for ALIVUS, SUDEEPPHRM | medium | “it became clear that only 50% of our U.S. business is subject to the announced tariff” SUDEEPPHRM passed on tariff impacts to 90% of customers; ALIVUS views its fine as a one-off. |
| China's elimination of VAT rebates on exports could increase global prices for competing products.Named for SUDEEPPHRM | low | “China had announced the elimination of the VAT rebate. ... I think it's gone up maybe 15%-20%” Management views this as supporting the narrative for an ex-China supply chain. |
| Need for localized stocking to improve service levels in international markets.Named for SUDEEPPHRM | low | “the company has recently commenced warehousing operations in USA and Europe to improve service level and responsiveness.” Commenced warehousing operations in the USA and Europe. |
| Double hit from Renminbi strengthening and Rupee weakening against the USD.Named for ALIVUS | low | “Renminbi is strengthening against the dollar and then the Rupee is weakening against the dollar. So, we have a kind of a double hit.” 6-month contracts and a distributed supply base are in place. |
Sources: our Pharmaceuticals Bulk Drugs & Formulation sector brief, 19 Apr 2026 · company earnings-call transcripts.
06 · compare level, then change
Revenue Scale & Growth Durability
Alivus Life Sciences Ltd has the highest Revenue among the 2 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at ₹2,590 crore. Amanta Healthcare Ltd is next at ₹291 crore. The same company also holds the highest Revenue growth, at 7.9%. 2 of 2 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Alivus Life Sciences Ltd is the scale leader at ₹2,590 crore, 789.4% ahead of Amanta Healthcare Ltd. Alivus Life Sciences Ltd's growth is 7.9% from a ₹2,590 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderAlivus Life Sciences Ltd · ₹2,590 crore
Gap789.4% versus #2 · Amanta Healthcare Ltd
Persistence7/8 recent comparable periods
Coverage2/2 companies · 29 observations
Investor read: Alivus Life Sciences Ltd is the scale benchmark; Alivus Life Sciences Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Alivus Life Sciences Ltd's growth falls below Alivus Life Sciences Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
2/2 level · 2/2 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Alivus Life Sciences Ltd ALIVUS | ₹640 Cr | 6.3% | Jun 2026 |
| Amanta Healthcare Ltd AMANTA⚠ unverified | ₹69 Cr | 5.3% | Jun 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
₹68 Cr
₹67 Cr
₹68 Cr
₹72 Cr
₹65 Cr
₹71 Cr
₹74 Cr
₹77 Cr
₹69 Cr
Revenue growth · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
—
—
—
-6.7%
-9.4%
3.6%
21%
18%
17%
5.9%
-14%
1.9%
-15%
12%
21%
2.2%
16%
4.8%
6.0%
6.3%
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-4.1%
6.2%
9.9%
6.8%
5.3%
07 · compare level, then change
Operating Economics & Margin Trend
Alivus Life Sciences Ltd has the highest OPM among the 2 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at 33%. Amanta Healthcare Ltd is next at 21.1%. The same company also holds the highest Margin change, at +4 percentage points. 2 of 2 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Alivus Life Sciences Ltd leads both opm at 33% and margin change at +4 percentage points.
LeaderAlivus Life Sciences Ltd · 33%
Gap56.4% versus #2 · Amanta Healthcare Ltd
Persistence5/8 recent comparable periods
Coverage2/2 companies · 29 observations
Investor read: Alivus Life Sciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
Margin changefastest expanders
Operating margin · company comparison
2/2 level · 2/2 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Alivus Life Sciences Ltd ALIVUS | 33% | +4.0 pp | Jun 2026 |
| Amanta Healthcare Ltd AMANTA⚠ unverified | 21% | −1.7 pp | Jun 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
30%
28%
28%
30%
28%
27%
33%
33%
28%
30%
26%
27%
27%
30%
31%
29%
30%
34%
31%
33%
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
20%
21%
22%
26%
23%
21%
21%
19%
21%
Margin change · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
+5.4 pp
−3.0 pp
−8.7 pp
−0.6 pp
−1.6 pp
−1.0 pp
+5.3 pp
+3.0 pp
−0.2 pp
+3.0 pp
−7.0 pp
−6.0 pp
−1.0 pp
0.0 pp
+5.0 pp
+2.0 pp
+3.0 pp
+4.0 pp
0.0 pp
+4.0 pp
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+3.1 pp
−0.1 pp
−1.6 pp
−6.9 pp
−1.7 pp
08 · compare level, then change
Profit Scale & Acceleration
Alivus Life Sciences Ltd has the highest Net profit among the 2 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at ₹603 crore. Amanta Healthcare Ltd is next at ₹15 crore. The same company also holds the highest Profit growth, at 21.6%. 2 of 2 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Alivus Life Sciences Ltd leads with ₹603 crore of TTM profit, 41× the profit of Amanta Healthcare Ltd. Alivus Life Sciences Ltd shows 21.6% growth from a ₹603 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderAlivus Life Sciences Ltd · ₹603 crore
Gap41× versus #2 · Amanta Healthcare Ltd
Persistence7/8 recent comparable periods
Coverage2/2 companies · 29 observations
Investor read: Alivus Life Sciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
Net profit · company comparison
2/2 level · 2/2 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Alivus Life Sciences Ltd ALIVUS | ₹160 Cr | 31% | Jun 2026 |
| Amanta Healthcare Ltd AMANTA⚠ unverified | ₹3 Cr | -5.7% | Jun 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
₹115 Cr
₹104 Cr
₹99 Cr
₹109 Cr
₹107 Cr
₹105 Cr
₹146 Cr
₹135 Cr
₹119 Cr
₹119 Cr
₹98 Cr
₹111 Cr
₹95 Cr
₹137 Cr
₹142 Cr
₹122 Cr
₹130 Cr
₹150 Cr
₹163 Cr
₹160 Cr
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
₹-0 Cr
₹2 Cr
₹4 Cr
₹6 Cr
₹4 Cr
₹1 Cr
₹5 Cr
₹6 Cr
₹3 Cr
Profit growth · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
—
—
—
7.9%
-7.0%
1.0%
47%
24%
11%
13%
-33%
-18%
-20%
15%
45%
9.9%
37%
9.5%
15%
31%
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-46%
8.2%
-7.2%
-5.7%
09 · compare level, then change
Return On Capital Employed
Alivus Life Sciences Ltd has the highest ROCE among the 2 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at 23.8%. Amanta Healthcare Ltd is next at 11.6%. The same company also holds the highest ROCE change, at -0.4 percentage points. 2 of 2 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Alivus Life Sciences Ltd leads ROCE at 23.8%, 12.2 percentage points above Amanta Healthcare Ltd. Alivus Life Sciences Ltd has the strongest latest improvement at -0.4 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderAlivus Life Sciences Ltd · 23.8%
Gap105.2% versus #2 · Amanta Healthcare Ltd
Persistence2/8 recent comparable periods
Coverage2/2 companies · 21 observations
Investor read: Alivus Life Sciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCE changefastest improvers
Return on capital · company comparison
2/2 level · 2/2 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Alivus Life Sciences Ltd ALIVUS | 21% | −0.4 pp | Jun 2026 |
| Amanta Healthcare Ltd AMANTA⚠ unverified | 9.9% | −6.2 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
31%
—
28%
—
25%
—
27%
—
27%
30%
26%
26%
21%
23%
21%
25%
21%
25%
21%
—
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
10%
16%
17%
12%
14%
9.9%
—
ROCE change · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
—
—
—
—
−6.0 pp
—
−0.5 pp
—
+2.4 pp
—
−1.4 pp
—
−6.0 pp
−6.9 pp
−4.6 pp
−1.0 pp
+0.3 pp
+2.0 pp
−0.4 pp
—
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+3.4 pp
−6.2 pp
—
10 · compare level, then change
Valuation Against Growth & Quality
Alivus Life Sciences Ltd has the lowest PEG among the 2 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at 1.17×. The same company also holds the lowest P/E, at 27.4×. 1 of 2 companies report a comparable reading, the latest through Jun 2026. Its PEG series carries 10 reported observations across the 20-quarter window.
What the numbers say: Alivus Life Sciences Ltd has the lowest comparable PEG at 1.17×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderAlivus Life Sciences Ltd · 1.17×
GapNot enough peers
Persistence0/8 recent comparable periods
Coverage1/2 companies · 10 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
Valuation · company comparison
1/2 level · 2/2 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Alivus Life Sciences Ltd ALIVUS | 1.2 | 23.3 | Jun 2026 |
| Amanta Healthcare Ltd AMANTA⚠ unverified | — | 43.9 | Jun 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
0.0
—
—
—
—
—
0.2
1.9
1.0
1.2
—
—
—
1.9
—
—
2.1
0.8
0.8
1.2
P/E · reported quarter history
Alivus Life Sciences Ltd · ALIVUS
1.9
1.8
3.7
12.5
11.1
12.3
11.5
14.9
15.3
15.9
18.3
22.6
28.2
28.6
30.0
25.3
23.2
21.0
21.4
23.3
Amanta Healthcare Ltd · AMANTA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
37.2
29.7
27.2
43.9
11 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Pharmaceuticals Bulk Drugs & Formulation comparison names 6 specific ways its own evidence can mislead, all listed below. All 2 companies here report on comparable dates, so no rank carries a stale marker. 1 draws at least one figure from a second feed with too little overlap to cross-check. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears.
- Thin comparisons: Valuation have fewer than three usable current readings.
12 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 2 Pharmaceuticals Bulk Drugs & Formulation companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-14.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-14 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing1 cross-checked · 1 unverified · 0 withheld, of 2 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
13 · questions investors ask, short speakable answers
Pharmaceuticals Bulk Drugs & Formulation company comparison FAQs
These 23 answers restate the Pharmaceuticals Bulk Drugs & Formulation comparison above in question form. Every one is computed from the same 2 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-14. Nothing here is estimated, and none of it is a recommendation.
Is the Pharmaceuticals Bulk Drugs & Formulation sector outperforming NIFTY 500?
Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over 52 weeks and 22.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself.
Which Pharmaceuticals Bulk Drugs & Formulation company is largest by revenue?
Alivus Life Sciences Ltd leads with revenue of ₹2,590 crore, based on 2 of 2 comparable companies through Jun 2026.
Which Pharmaceuticals Bulk Drugs & Formulation company is growing fastest?
Alivus Life Sciences Ltd has the fastest current revenue growth at 7.9%, across 2 of 2 comparable companies.
Which Pharmaceuticals Bulk Drugs & Formulation company has the strongest 4-Factor Sector Score?
Alivus Life Sciences Ltd ranks first at 72.5/100 with 97% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Pharmaceuticals Bulk Drugs & Formulation company has the lowest comparable PEG?
Alivus Life Sciences Ltd has the lowest comparable PEG at 1.17, among 1 of 2 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Pharmaceuticals Bulk Drugs & Formulation comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Pharmaceuticals Bulk Drugs & Formulation index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharmaceuticals Bulk Drugs & Formulation, this page builds its own equal-weight basket of 2 listed Pharmaceuticals Bulk Drugs & Formulation companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Pharmaceuticals Bulk Drugs & Formulation stocks in India?
Ranked by this page's four-factor score, Alivus Life Sciences Ltd places first among 2 listed Pharmaceuticals Bulk Drugs & Formulation companies, followed by Amanta Healthcare Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Pharmaceuticals Bulk Drugs & Formulation stocks are listed in India?
This comparison covers 2 listed Pharmaceuticals Bulk Drugs & Formulation companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Pharmaceuticals Bulk Drugs & Formulation company is the biggest?
Alivus Life Sciences Ltd is the largest, with trailing-twelve-month revenue of ₹2,590 crore, ahead of Amanta Healthcare Ltd at ₹291 crore. That covers 2 of 2 companies with comparable reporting through Jun 2026.
Which Pharmaceuticals Bulk Drugs & Formulation company has the best profit margins?
Alivus Life Sciences Ltd has the highest operating margin at 33%, from 2 of 2 comparable companies. Alivus Life Sciences Ltd shows the biggest recent improvement, at +4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Pharmaceuticals Bulk Drugs & Formulation company makes the most profit?
Alivus Life Sciences Ltd earns the most, at ₹603 crore of trailing-twelve-month net profit, from 2 of 2 comparable companies. Alivus Life Sciences Ltd has the fastest profit growth at 21.6%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Pharmaceuticals Bulk Drugs & Formulation company earns the highest return on capital?
Alivus Life Sciences Ltd leads on return on capital employed at 23.8%, across 2 of 2 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Pharmaceuticals Bulk Drugs & Formulation stock is the cheapest?
On PEG — where a LOWER number is cheaper — Alivus Life Sciences Ltd screens cheapest at 1.17×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Pharmaceuticals Bulk Drugs & Formulation sector beating the market?
Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over the last 52 weeks and 22.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Pharmaceuticals Bulk Drugs & Formulation stock has the strongest price momentum?
Alivus Life Sciences Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Pharmaceuticals Bulk Drugs & Formulation company scores highest for research priority?
Alivus Life Sciences Ltd scores 72.5 out of 100 with 97% evidence confidence, from 22.6 points on growth and earnings, 20 on capital efficiency, 11.2 on valuation and 18.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Pharmaceuticals Bulk Drugs & Formulation companies does this comparison cover, and over what period?
It compares 2 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Pharmaceuticals Bulk Drugs & Formulation sector?
The 2 Pharmaceuticals Bulk Drugs & Formulation companies on this page carry ₹17,632 crore of combined market value. Alivus Life Sciences Ltd is the largest at ₹17,025 crore, about 97% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20.
How is the Pharmaceuticals Bulk Drugs & Formulation sector performing?
1 of the 1 covered Pharmaceuticals Bulk Drugs & Formulation companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 27.5% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.